CARB-X Funds Pattern Bioscience to develop a new rapid diagnostic for drug-resistant bacterial infections
CARB-X is awarding Pattern Bioscience (formerly operating as Klaris Diagnostics), based in Austin, Texas, US, up to US$6.8 million in non-dilutive funding to develop a rapid identification and antimicrobial susceptibility test (ID/AST) to diagnose drug resistant infections quickly, and provide health professionals with vital information about which pathogen is causing the infection and which antibiotic is most likely to cure the infection.
If the project successfully achieves certain development milestones, Pattern will be eligible for up to an additional $15.1 million in funding from CARB-X. CARB-X is a consortium led by Boston University and funded by a global partnership.
Display your AMR technology / product:
Global AMR Technologies Database
- Preventive – Diagnostic – Antimicrobial technologies
- Academia – Research Institutes – Start ups – SMEs – Multinationals
- Early research <-> near market (max 5)
- Global reach for funding / co-development / licensing